Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

(Reuters) -The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory-robbing disease.

These are some of the areas where Eli Lilly, flush with cash from its GLP ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory ...

At a time when global coordination against health threats is critical, recent policy shifts in the U.S. have created a ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

The peptides activate receptors of a gut hormone called GLP-1, while the antibody blocks receptors of another hormone called GIP. That's unlike Eli Lilly's obesity drug, Zepbound, which activates ...